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Helicobacter pylori is an important human pathogen which
causes both gastric and duodenal ulcers and is associated with
gastric cancer and lymphoma. This microorganism synthesizes
fucosylated oligosaccharides, predominantly the Gal-
1,4GlcNAc (Type II) blood group antigens Lewis X and Y,
whereas a small population also expresses the Gal-
1,3GlcNAc (Type I) blood group antigens Lewis A and B.
These carbohydrate structures are known to mimic host cell
antigens and permit the bacteria to escape from the host
immune response. Here, we report the cloning and character-
ization of a novel H. pylori -1,4 fucosyltransferase (FucT).
In contrast to the family members characterized to date, this
enzyme shows exclusively Type I acceptor substrate specificity.
The enzyme consisting of 432 amino acids (MW 50,502 Da)
was cloned using a polymerase chain reaction (PCR)-based
approach. It exhibits a high degree of identity (75–87%) and
similar structural features, for example, in the heptamer
repeat pattern, with other H. pylori FucTs. The kinetic char-
acterization revealed a very efficient transferase (kcat/Km =
229 mM1s1) for the Type I acceptor substrate (Gal)-1,3
GlcNAc-Lem (1). Additionally, the enzyme possesses a broad
tolerance toward nonnatural Type I acceptor substrate
analogs and therefore represents a valuable tool for the
chemoenzymatic synthesis of Lewis A, sialyl Lewis A as well
as mimetics thereof.
Key words: enzymatic synthesis/Helicobacter pylori/sialy 
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Introduction
Fucosyltransferases (FucTs) are the enzymes responsible
for the last step in the synthesis of Lewis antigens. They cat-
alyze the transfer of fucose (Fuc) from guanidine 5′-diphos-
pho-β-L-fucose (GDP-fucose) to oligosaccharide acceptors
to form α1,2 (Larsen et al., 1990), α1,3 (Weston et al.,
1992), and α1,4 linkages (Kukowska-Latallo et al., 1990).
Although the chemical synthesis of carbohydrates is well
developed (for reviews, see Ernst et al., 2000a), the prepara-
tion of a particular oligosaccharide still remains a costly
and cumbersome challenge. A complementary approach
to the chemical synthesis of physiologically important
oligosaccharides is the combined use of chemical and
enzymatic methods. It has also been shown that glycosyl-
transferases can be successfully employed for the synthesis
of a wide range of nonnatural oligosaccharides as well
(Palcic and Hindsgaul, 1991; Baisch et al., 1996a,b,c; Gijsen
et al., 1996; Ernst and Oehrlein, 1999; Ernst et al., 2000b;
Seto et al., 2000; Blixt et al., 2002; Bintein et al., 2003). For
their heterologous production mammalian (Larsen et al.,
1990; Kitagawa and Paulson, 1994) and baculovirus expres-
sion systems (Morais et al., 2001; Kim et al., 2003) as well
as yeast (Malissard et al., 2000) have been used.
Recently, several reports demonstrated the ability of
human pathogenic bacteria such as Helicobacter pylori
(Chan et al., 1995; Martin et al., 1997; Monteiro et al.,
1998; Wang et al., 2000), Campylobacter jejunii (Gilbert
et al., 2000), Neisseria gonorrhoeae, and Neisseria meningitis
(Gilbert et al., 1996) to synthesize Lewis A and B as well as
Lewis X and Y blood group antigens. As constituents of
membrane lipopolysaccharides, these oligosaccharides
mimic the host cell antigens and permit the bacterium to
escape from the immune response (Appelmelk et al., 1996;
Wirth et al., 1996; Gilbert et al., 2000). The sequenced
genome of two strains of the gastric pathogenic bacterium
H. pylori revealed many putative FucT sequences (Tomb
et al., 1997; Alm et al., 1999). As a consequence, the cloning
and expression of H. pylori α-1,2 (Wang et al., 1999), α-1,3
(Ge et al., 1997; Martin et al., 1997) and α-1,3/4 FucTs
(Rasko et al., 2000) has been reported.
Our interest in glycosyltransferases for the preparative
chemoenzymatic synthesis of carbohydrates prompted us to
search for cost effective sources. In this study, we report the
cloning, functional expression, and characterization of a
novel H. pylori α-1,4 FucT in Escherichia coli and its
preliminary use for the chemoenzymatic synthesis of
Lewis A, Galβ-1,3(Fucα-1,4)GlcNAc (Lea), sialyl Lewis A,
NeuNAcα-2,3Galβ-1,3(Fucα-1,4)GlcNAc (sLea), and mimet-
ics thereof.
Results
Cloning of a H. pylori fucosyltransferase
In order to clone a gene encoding an α-1,3 or α-1,3/4 FucT
in H. pylori strain DMS 6709, primers derived from the
highly homologous H. pylori FucT sequences available in
1To whom correspondence should be addressed; e-mail:
beat.ernst@unibas.ch
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NCBI Genbank (AF194963, AAD06573 and AAD06169)
were designed and used to amplify a PCR product of 1375 bp.
The fragment was double-digested by EcoRI/BamHI and
cloned into the expression vector pEZZ18. This vector
offers the advantage of generating a recombinant protein
containing two synthetic IgG-binding domains (ZZ) of
Staphylococcus aureus protein A and an export signal for
protein secretion in the culture medium. After transformation
in E. coli, five positive clones were selected according to
PCR and restriction enzyme control. The sequence of their
first 400–500 bp from the N-terminus showed 100% identity
at the amino acid level. Protein expression was carried out
with three clones resulting in a secreted fusion ZZ-FucT
polypeptide with a calculated molecular mass of 64,502 Da.
FucT without ZZ-fusion domain encodes a 436-amino acid
polypeptide with a predicted molecular mass of 50,502 Da.
The full nucleotide sequence for one clone was confirmed
by the double-stranded sequencing strategy and registered
at the GenBank™ /EBI Data Bank (AY450598).
Features of the novel H. pylori fucosyltransferase sequence
The nucleotide and the deduced amino acid sequence of the
cloned FucT are shown in Figure 1A. The Kyte–Doolittle
plot analysis shows a very hydrophilic protein without any
transmembrane segments (Figure 1B). A sequence blast of
our new FucT against the H. pylori genomes of J99 and
26695 strains demonstrates a high degree of similarity to
two FucTs in strain J99 (NP223719.1 and NP223314.1) and
two α-1,3 FucTs in strain 26695 (NP207177.1 and
NP207445.1). The alignment of the amino acid sequence
revealed a high degree of similarity to other H. pylori
FucTs, for example 87% identity to the α-1,3 FucT (Martin
et al., 1997) and 75% identity to the α-1,3/4 FucT (Rasko
et al., 2000). This is in agreement with human FucTs sharing
a high level of amino acid sequence similarity even when
they exhibit distinct acceptor substrate specificities
(Kukowska-Latallo et al., 1990; Weston et al., 1992; Xu et al.,
1996). In analogy to other H. pylori FucT sequences, the
new FucT also contains repetitive sequences of the hep-
tapeptide DDLRINY close to the C-terminus (Figure 1A).
However, there are only four instead of seven, eight or ten
repeats observed in H. pylori α-1,3 FucT (strain
NCTC11637, Chan et al., 1995), H. pylori α-1,3/4 Fuc
(strain UA948, Rasko et al., 2000), and H. pylori α-1,3
FucT (strain NCTC11639, Ge et al., 1997), respectively.
The intervals between the leucines show a high regularity
similar to the eukaryotic leucine zipper motif, which is
believed to be involved in protein–protein and protein–
DNA interactions (Landschulz et al., 1988). The peptide
motif YxFxLxFENSxxxxYxTEK found in H. pylori α-1,3/4
FucT (Rasko et al., 2000) as well as in the bovine FucT III
(Oulmouden et al., 1997), the panther FucT III (Costache
et al., 1997), human α-1,3/4 FucT (FucT III, Kukowska-
Latallo et al., 1990), and human α-1,3 FucT (FucT V,
Weston et al., 1992) is also conserved in the novel H. pylori
FucT sequence (Figure 1A and C). Finally, in the reported
H. pylori FucT a peptide sequence (343–352 : CDAH-
NYSALH) similar to H. pylori α-1,3/4 FucT (345–354:
CNDAHYSALH) is present (Ma et al., 2003) (Figure 1A). It
seems to be related to the acceptor specificity.
Fig. 1. (A) Nucleotide sequence and deduced amino acids sequence of the 
novel Helicobacter pylori α-1,4 fucosyltransferase (FucT). The heptamer-
repeat motifs are underlined and in boldface type. Residues denoted by 
boldface type represent the conserved α-1,3 (Martin et al., 1997) and α-1,3/4 
FucT (Rasko et al., 2000) motifs. Residues denoted in italic and boldface 
type seem to govern the Galβ-1,3GlcNAc (Type I) acceptor substrate spec-
ificity (Ma et al., 2003). (B) Kyte–Doolittle hydropathy profile of the novel 
H. pylori α-1,4 FucT based on the DNA sequence. The enzyme shows a 
very hydrophilic profile without any transmembrane segments. (C) Amino 
acid sequence alignment of the bovine (Q11126), panther (O19058), human 
FucT III (P21217), human FucT V (Q11128), and H. pylori α-1,3/4 FucT 
(Q9L8S4) with the novel H. pylori α-1,4 FucT. The conserved α-1,3/4 
FucTs peptide motif is indicated in boldface type.
(B)
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Expression and affinity purification of the recombinant 
soluble H. pylori fucosyltransferase
The vector containing the recombinant enzyme was
transformed into the E. coli strains Top10, DHα5, and
AD494. The AD494 strain cultivated in TB medium
showed the highest level of enzyme expression (5 mg/L
and 5U/mg) and therefore was used for further enzyme
production. E. coli AD494 strain is a thioredoxin reduc-
tase mutant that enables disulfide bond formation and
thus provides the potential to produce properly folded
proteins (Derman et al., 1993). The soluble enzyme
secreted in the culture medium was recovered in a one
step procedure by affinity chromatography using a GDP-
hexanolamine column leading to much higher yields of
active FucT than affinity purification with IgG sepharose
(data not shown). The recombinant enzyme was stable
for several months at −70°C in cacodylate buffer contain-
ing 10% glycerol.
Sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis analysis
To verify the degree of purification, the novel FucT was
analyzed by 10% sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS–PAGE) followed by silver stain-
ing showing a single band at the expected molecular mass of
approximately 64.50 kDa (Figure 2). In addition, Figure 2
also shows the difference in the level of FucT expression in
E. coli AD494 (clone 1) as compared to other strains (DHα5
and Top10).
Acceptor specificity of the recombinant soluble 
H. pylori FucT
To determine the specificity of the novel FucT, Galβ-
1,3GlcNAc (Type I) and Galβ-1,4GlcNAc (Type II) disac-
charides as well as their α-2,3 sialylated forms were used as
acceptors and GDP-fucose as donor (Figure 3). All accep-
tor substrates contain the lipophilic Lemieux substituent
(Lem : O(CH2)8COOMe) at the reducing end to facilitate
the purification of the fucosylated products on Sep–Pak-C18
cartridges (Hindsgaul et al., 1991). The kinetic parameters
Km and kcat obtained are summarized in Table I. Under
standard conditions, the novel transferase showed excellent
activity with the Type I acceptor substrates 1 and 2,
whereas the Type II acceptor substrates 3 and 4 were only
moderately fucosylated even at acceptor substrate concen-
trations of 2 mM. Thus, the novel bacterial enzyme showed
the properties of an α-1,4 FucT, although the primers used
for the sequence generation were derived from α-1,3 and
α-1,3/4 FucT sequences. This is, however, not astonishing,
because high homologies of H. pylori FucT sequences are
known for the human enzymes. Similar to the human
α-1,3/4 FucT (Kukowska-Latallo et al., 1990), H. pylori
α-1,4 FucT accepted 3′-sialyl-lacto-N-biose (2) slightly
better than lacto-N-biose (1). The affinity of the enzyme
for the GDP-fucose was very high (Km = 5.73 µM). In
general, depending on the strains (UA 861, UA 802, and
UA 1182 [Chan et al., 1995] and NCTC 11637 [Martin
et al., 1997]), the affinity of bacterial enzymes for GDP-
fucose varies from 17 to 140 µM (Chan et al., 1995; Ma
et al., 2003).
To study the applicability of the novel α-1,4 FucT to the
preparative enzymatic syntheses of sLea mimetics, modified
Type I oligosaccharides containing replacements of the
GlcNAc and/or N-acetylneuraminic acid (NeuNAc) moiety
by noncarbohydrate structures were evaluated. The enzy-
matic activity was quantified as the amount of radioactivity
transferred from GDP-L-[14C]Fuc to the corresponding
acceptor (in % relative to 1, Table II). The pseudotrisaccha-
ride 5, in which GlcNAc is substituted by (R,R)-cyclo-
hexan-1,2-diol and NeuNAc by (R)-cyclohexyllactic acid
showed only minimal acceptor properties (5.1%). The
(S)-lactic acid derivative 6, however, proved to be an excel-
lent acceptor substrate (100%). The activity was practically
abolished when compound 8 [GlcNAc moiety replaced by
(R,R)-butan-2,3-diol and NeuNAc by (S)-3-phenyllactic
acid] was used as acceptor substrate. Finally, reduced activity
Fig. 1. continued
(C)
Fig. 2. Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–
PAGE) analysis of affinity purified H. pylori α-1,4 fucosyltransferase. The 
enzyme was expressed in AD494, DHα5, and Top10 Escherichia coli cells. 
Single colonies from each clone (1, 2, 3, and 4) were grown overnight at 
37°C and by vigorous shaking (300 rpm) in Terrific Broth medium (TB). 
The protein purification was performed as described in Materials and 
methods. Equal volumes (10 µL) from the eluted fractions were separated 
on 10% SDS–PAGE followed by silver staining. The molecular weight 
marker (MWM) is indicated on the left.
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was also observed with the acceptor substrates 7 (8.6%) and
9 (2.8%).
N-ethylmaleimide inhibition assays and thermal stability
FucTs have been discriminated according to their sensitiv-
ity to the sulfhydryl-binding reagent N-ethylmaleimide,
NEM (Chou et al., 1977; Campbell and Stanley, 1984). The
human Lewis (FucT III) and the plasma-type (FucT VI)
enzymes are inhibited by NEM, whereas others such as the
myeloid-type enzyme (FucT IV) are insensitive to NEM
treatment (Holmes et al., 1995). The sensitivity of the novel
bacterial α-1,4 FucT to NEM was very high, as 90% of the
enzyme activity was abolished in the presence of 10 mM
NEM (Figure 4). In contrast, it has been shown that
Fig. 3. Structures of natural (1 and 2) and nonnatural substrates (3–9).
Table I. Acceptor substrate specificity of the novel Helicobacter pylori 
α-1,4 fucosyltransferase: relative enzyme activity (100% correspond to the 
transfer of 3.76 µmol fucose/mg protein/min)
The assay was conducted as described in Materials and methods.
Acceptors Km (µM) kcat (s−1)
kcat/Km
(mM−1s−1)
Galβ-1,3GlcNAc-R (1) 114 26.12 229
Siaα-2,3Galβ-1,3GlcNAc-R (2) 111 34.33 310
Galβ-1,4GlcNAc-R (3) 313 0.067 0.21
Siaα-2,3Galβ-1,4GlcNAc-R (4) 432 0.114 0.26
GDP-fucose 5.73 3.947 689
Table II. Enzyme activity of the novel Helicobacter pylori α-1,4 fucosyl-
transferase with Galβ-1,3GlcNAc (Type I) and Galβ-1,4GlcNAc (Type II) 
acceptor
The fucosyltransferase assay was run in duplicates using Type I or Type II 
acceptors and 0.150 mM 5′-diphospho-β-L-fucose (GDP-fucose). For the 
determination of the Km for GDP-fucose, 2 mM of Type I acceptor 
substrate 1 was used. The reactions were quantified as described in 
Materials and methods.
Acceptors Relative activity (%)
1 100
2 133
3 0.3
4 2.7
5 5.1
6 100
7 8.6
8 0.9
9 2.8
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H. pylori α-1,3 FucT is only minimally inhibited by NEM
(Martin et al., 1997).
As next, the applicability of the novel FucT at elevated
temperature was tested. The recombinant α-1,4 FucT
shows maximal activity between 37 and 42°C, below (25°C,
70%) and above (50°C, 60%) the catalytic activity was
slightly reduced. This is in contrast to human FucT VII
(α-1,4 FucT) expressed in Sf9 insect cells (Shinkai et al., 1997),
which shows a more pronounced deactivation at elevated
temperatures (50°C, 35%).
Discussion
Recently, several putative FucT sequences have been identi-
fied in the genome of H. pylori (Tomb et al., 1997; Alm
et al., 1999). Consequently, considerable attention has been
devoted to this bacterium to understand the molecular
mechanism of pathogenicity but also to use it as a cost
effective source of glycosyltransferases. Helicobacter pylori
strains express on their surface predominantly lipopolysac-
charides containing Type II Lewis antigens (Wirth et al.,
1996; Simoons-Smit et al., 1996). Type I Lewis antigens,
however, are found only in a limited number of strains
(Wirth et al., 1996; Monteiro et al., 1998).
In this study, we report the molecular cloning, functional
expression and characterization of a novel H. pylori α-1,4
FucT. Analysis of the predicted protein sequence revealed a
high degree of identity to other H. pylori, for example,
α-1,3 (Martin et al., 1997; Ge et al., 1997) and α-1,3/4
FucTs (Rasko et al., 2000). Within the FucT family the
high level of sequence homology does not correlate with
their substrate specificities (Kukowska-Latallo et al., 1990;
Weston et al., 1992). Similar to other H. pylori FucT
sequences, there is a direct repeat of heptamers close to the
C-terminus. However, the number of these repeats is lim-
ited to four instead of seven, eight or ten found in other
H. pylori FucTs (Ge et al., 1997; Martin et al., 1997; Rasko
et al., 2000). The influence of the number of heptameric
repeats on the substrate specificity has not been investi-
gated yet. However, the deletion of the ten repeat motifs in
H. pylori strain NCTC11639 (Ge et al., 1997) generates an
inactive transferase, suggesting a role of these motifs in the
enzyme function.
Recently, Ma et al. (2003) reported the construction of
enzyme chimeras by subdomain swapping between α-1,3
and α-1,3/4 H. pylori FucTs. The result indicates that Type I
acceptor specificity seems to be governed by ten amino
acids (CNDAHYSALH) corresponding to residues 345–
354 in α-1,3/4 FucT. In the reported H. pylori α-1,4 FucT a
similar peptide sequence (343–352) is present (Figure 1A).
The expression of the novel H. pylori FucT in E. coli
AD494 cells yields an enzyme, which fucosylates Galβ-
1,3GlcNAcβ-Lem (1) and its α-2,3 sialylated form 2 with
high efficiency (Table I). However, even at acceptor sub-
strate concentrations up to 2 mM, the activity with the
N-acetyllactosamine (LacNAc) derivatives 3 and 4 was not
significant (0.3–2.7%). In contrast to the activity of the
H. pylori α-1,3/4 FucT, which is 5 to 20-fold higher with
LacNAc compared to the Type I acceptor substrate lacto-
N-biose (Rasko et al., 2000), the novel H. pylori FucT
shows an almost exclusive acceptance for Type I substrates.
In preliminary experiments for the preparative chemoenzy-
matic synthesis of sLea/x mimetics as potential E-selectin
antagonists, the novel H. pylori FucT showed a remarkable
tolerance for a variety of nonnatural acceptor substrates
(Figure 3, Table II). Although some of the activities were
relatively weak, they are still sufficient for a preparative
enzymatic approach. Furthermore, these results suggest
that NeuNAc can be substituted by analogs with an appro-
priate stereochemistry, for example [S]-lactic acid derivatives.
In addition, these replacements are also tolerated in combi-
nation with GlcNAc mimetics such as (R,R)-butan-2,3-diol or
(R,R)-cyclohexan-1,2-diol.
Besides their acceptor substrate specificity, FucTs have
been classified according to their sensitivity toward NEM,
which is known to modify proteins by forming a covalent
linkage with the sulfhydryl group of cysteine residues
(Chou et al., 1977; Campbell and Stanley, 1984). Our bacte-
rial α-1,4 FucT was inhibited to 90% with 10 mM NEM,
whereas the activity of the H. pylori α-1,3 FucT was
reduced by only 35% in the presence of 15 mM NEM
(Martin et al., 1997). This is in accordance with the data
obtained for the corresponding human FucTs (Holmes
et al., 1995). Examination of the cysteine distribution within
the two highly homologous H. pylori enzymes (87% iden-
tity) shows two conserved cysteines (Cys164 and Cys233 in
α-1,4 FucT and Cys168 and Cys237 in α-1,3 FucT) as well
as a third cysteine, which is located differently in the two
sequences (α-1,4 FucT : Cys343; α-1,3 FucT : Cys282).
Site-directed mutagenesis analysis should provide the infor-
mation on the cysteine residue responsible for sensitivity
toward NEM.
Finally, it has been shown that differences in N-glycosy-
lation affect the thermal stability of FucTs. Therefore,
depending on the expression system, FucTs show different
thermal profiles, for example Sf9 verus Namalwa KJM-1
cells (Shinkai et al., 1997). Interestingly, the catalytic activity
Fig. 4. N-ethylmaleimide (NEM) inhibition of the novel Helicobacter 
pylori α-1,4 fucosyltransferase. NEM was added to the ice-cooled reaction 
30 min before incubation with Galβ-1,3GlcNAcβLem (1) to give final con-
centrations of 0.5–10 mM. The enzymatic reaction was quantified as 
described in Materials and methods.
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of H. pylori α-1,4 FucT expressed in E. coli is only slightly
affected by elevated temperatures.
In summary, this study reports the complete gene
sequence of a novel α-1,4 FucT. Sequence comparison indi-
cates high similarity with other H. pylori FucTs and to a
lower extent with eukaryotic FucTs. The enzyme catalyzes
almost exclusively the fucosylation of Type I acceptor sub-
strate and mimetics thereof. Whereas active mammalian
FucTs cannot be expressed in E. coli because of the lack of
glycosylation (Kukowska-Latallo et al., 1990; Larsen et al.,
1990), the expression of active H. pylori α-1,4 FucT is pos-
sible. This allows the cost-effective bacterial production of
FucTs in preparative amounts and their use in large-scale
enzymatic syntheses of oligosaccharides.
Materials and methods
Materials
The H. pylori strain was isolated from endoscopic biopsies
at the University Hospital, Gävle, Sweden and deposited by
Hoffmann-La Roche, Basel, Switzerland, under the num-
ber DMS6709 at the Deutsche Sammlung von Mikroorgan-
ismen, Braunschweig, Germany. Escherichia coli JM109,
DHα5, Top10, and AD494 strains have been purchased from
Novagen (Lucerne, Switzerland). Ampicillin, kanamycin and
protein standard bovine serum albumin (BSA) were obtained
from Sigma (Buchs SG, Switzerland). IgG sepharose column
material and GDP-L-[14C]fucose (287 mCi/mmol) were pur-
chased from Amersham Biosciences (Otelfingen, Switzerland).
GDP-hexanolamine was synthesized as described (Bamford
et al., 1996) and was coupled to cyanogen bromide-activated
sepharose 4B. Type I and Type II acceptor substrates and
analogs thereof have been chemically synthesized as des-
cribed (Hindsgaul et al., 1991; Ernst and Oehrlein, 1999;
Ernst et al., 2000b).
Cloning and expression of H. pylori α-1,4 fucosyltransferase
Helicobacter pylori genomic DNA was prepared using
the genomic DNA extraction kit from Wizard (Promega,
Wallisellen, Switzerland). The α-1,4 FucT gene was amplified
by PCR with the high fidelity pfu polymerase (Stratagene,
Amsterdam, The Netherlands). The forward and reverse
primers were designed on the basis of the published H. pylori
α-1,3 and α-1,3/4 FucT sequences (Accession numbers:
AF194963, AAD06573, and AAD06169). 5′-EcoRI forward
primer (5′-gcgaattcgatgttccagcccttactagacgctt-3′) and 5′-BamHI
reverse primer (5′-gccggatccctattaggaaagtagcgtctgcgat-3′) were
synthesized at Microsynth (Balgach, Switzerland). The PCR-
generated fragment (1375 bp) was treated with EcoRI and
BamHI and ligated (T4 DNA-ligase, Promega) into the
appropriate site of pEZZ18 cloning vector (Pharmacia-
Biotech, Otelfingen, Switzerland). Chemocompetent E. coli
JM109 cells were transformed with the ligation product,
plated on selective Luria-Betani-agar plates and incubated
overnight at 37°C. Single colonies were then inoculated in 2
mL LB-medium supplemented with 70 µg/mL ampicillin.
Plasmid DNA was isolated by minipreparation according to
the instructions of the supplier (GFX™ Micro Plasmid Prep
Kit, Amersham Biosciences). The constructs containing two
ZZ domains of protein A and the coding sequence for
H. pylori FucT were verified by PCR and restriction enzyme
digestion. DNA sequence analysis was performed by double-
stranded sequence reactions by Microsynth. The recombinant
vector was then transformed into the E. coli strains DHα5,
Top10, and AD494.
Bacterial culture and protein production
The bacterial clones containing the pEZZ18/FucT construct
were grown overnight with vigorous shaking (300 rpm)
at 37°C and in 50 mL Terrific Broth medium (TB, Becton
Dickinson, Basel, Switzerland) containing ampicillin
(70 µg/mL) and additionally kanamycin (25 µg/mL) for
AD494 cells. After 16 h the cells were collected by centrifu-
gation for 20 min at 5000 rpm and 4°C. Aliquots (5 mL)
from supernatants and cell lysates were concentrated by
ultrafiltration to 50 µL volume (Amicon YM 50) and tested
for enzyme activity.
Purification of H. pylori α-1,4 fucosyltransferase
The supernatant of the overnight bacterial culture was col-
lected by centrifugation and filtration (0.2 µm, Millipore,
Volketswil, Switzerland). The filtrate was adjusted to pH
7.6 with 2.5 M Tris–HCl solution. After loading the super-
natant on the IgG-sepharose–6 column (Pharmacia-Biotech)
attached to the BioLogic fast protein liquid chromatography
system (BioRad, Reinach BL, Switzerland) two washing
steps were performed, the first with 10 bed volumes of buffer
containing 50 mM Tris–HCl (pH 7.6), 150 mM NaCl, and
0.05% Tween 20 and the second with 2 bed volumes of
5 mM NH4OAc (pH 5.0). The enzyme was eluted with 10 mL
of 500 mM NH4OAc (pH 3.4). The collected fractions were
immediately neutralized with 2.5 M Tris–HCl solution and
concentrated by ultrafiltration (Amicon, YM 50) to a vol-
ume of 50 µL. In a second ultrafiltration step, the buffer was
exchanged by cacodylate buffer (pH 6.5).
In a second purification strategy, the supernatant of a
bacterial overnight culture was conditioned with 20 mM
MnCl2 and loaded on a GDP-hexanolamine column
according to the procedure described (De Vries et al., 2001).
The protein concentration of pooled active fractions was
determined by the Bradford assay using bovine serum
albumin (BSA, Sigma) as a standard.
SDS–PAGE analysis
Protein electrophoresis was performed on 10% polyacryla-
mide gel according to the method of Laemmli (1970). The
purity of eluted fractions was verified by silver-staining
(Silver staining Kit, Pharmacia-Biotech) using low molecular
weight marker (Sigma).
Fucosyltransferase assay
The reactions, run in duplicates, were conducted in a total
volume of 30 µL containing 50 mM cacodylate (pH 6.5),
20 mM MnCl2, 0.150 mM GDP-fucose, 55,000 cpm GDP-
[14C]fucose (287 mCi/mmol, Amersham Pharmacia), 3 µg
BSA (Sigma), 0.01 mM acceptor substrate, and 15 mU of
H. pylori α-1,4 FucT. After 30 min of incubation at 37°C,
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the reaction was stopped by the addition of 1 mL of water and
loaded onto a Sep–Pak-C18 cartridge (Waters, Rupperswil,
Switzerland). The cartridge was washed twice with 5 mL
bidistilled water and eluted with 5 mL methanol. The transfer
rate of [14C]Fuc onto the acceptor substrate was determined
by liquid scintillation counting. The activity of the enzyme
was calculated as a percentage of radioactivity counted in
the methanol fraction.
Determination of kinetic parameters
The kinetic parameters were determined using 0.150 mM of
GDP-fucose and concentrations of the acceptor substrates
ranging from 0.05 to 2 mM. For the determination of the
Km for GDP-fucose, the concentration of the Type I accep-
tor substrate 1 was kept at 2 mM. Reaction mixtures were
prepared as described above.
Thermal stability of the recombinant H. pylori α-1,4 
fucosyltransferase
The temperature stability of the enzyme was measured in
cacodylate buffer at pH 6.5 by preincubating the enzyme at
different temperatures ranging from 25 to 55°C for 5 min.
The reaction mixtures were then incubated for further
30 min at the indicated temperatures. The activity of the
enzyme was quantified as described above.
Treatment with NEM
To verify the susceptibility of the novel H. pylori α-1,4 FucT
to the sulfhydryl-binding reagent, various amounts of NEM
were added to the assay reaction to give final concentrations
of 0.5–10 mM. The reaction was cooled for 30 min on ice
before incubation with 1 and quantified as described above.
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